Cantor Fitzgerald Comments on Immunovant FY2025 Earnings

Immunovant, Inc. (NASDAQ:IMVT) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Immunovant in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn ($1.88) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Immunovant’s current full-year earnings is ($2.69) per share. Cantor Fitzgerald also issued estimates for Immunovant’s FY2026 earnings at ($2.92) EPS.

Several other equities research analysts have also weighed in on the company. Bank of America decreased their target price on Immunovant from $48.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday, January 15th. Wells Fargo & Company decreased their price objective on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Wolfe Research lowered Immunovant from an “outperform” rating to a “peer perform” rating in a research note on Friday, January 3rd. HC Wainwright restated a “buy” rating and issued a $51.00 price target on shares of Immunovant in a research report on Friday, February 7th. Finally, Guggenheim reduced their target price on Immunovant from $46.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Two research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $43.55.

Immunovant Stock Performance

IMVT opened at $19.42 on Thursday. The company has a market cap of $3.30 billion, a PE ratio of -7.41 and a beta of 0.68. The stock has a 50-day moving average of $22.06 and a 200-day moving average of $26.68. Immunovant has a 52-week low of $17.65 and a 52-week high of $35.97.

Immunovant (NASDAQ:IMVT) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.08).

Insider Activity

In other Immunovant news, CEO Peter Salzmann sold 5,105 shares of the stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $24.10, for a total value of $123,030.50. Following the completion of the sale, the chief executive officer now directly owns 972,992 shares in the company, valued at $23,449,107.20. This represents a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Eva Renee Barnett sold 4,105 shares of Immunovant stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $24.10, for a total value of $98,930.50. Following the transaction, the chief financial officer now owns 327,064 shares in the company, valued at $7,882,242.40. This trade represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,510 shares of company stock valued at $656,886 in the last quarter. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Immunovant

Institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in shares of Immunovant during the fourth quarter worth about $76,000. Two Seas Capital LP grew its stake in shares of Immunovant by 123.4% during the 4th quarter. Two Seas Capital LP now owns 1,511,614 shares of the company’s stock worth $37,443,000 after acquiring an additional 835,000 shares in the last quarter. Vestal Point Capital LP acquired a new stake in shares of Immunovant in the fourth quarter valued at approximately $1,115,000. Twinbeech Capital LP bought a new stake in shares of Immunovant in the fourth quarter worth $314,000. Finally, Two Sigma Advisers LP acquired a new position in Immunovant during the fourth quarter worth $270,000. 47.08% of the stock is owned by institutional investors.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.